VIVEbiotech to Expand Facilities for Lentiviral-Vector Manufacturing

Published on: 

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

VIVEbiotech, a gene transfer technologies contract development and manufacturing organization located in Spain, announced on Feb. 24, 2021 that it will be expanding its manufacturing capabilities with new facilities.

The expansion aims to increase the company’s production capacity and advance optimization of its manufacturing processes, the company said in a press release. A versatile design will allow flexible cleanroom configurations. Additionally, the facility expansions will provide the company with added space for upcoming projects.

“The continued expansion of the gene and cell therapy sector has resulted in an increase in the number of clinical trials, as well as additional trials moving into later-stage development. In turn, this has led to a continued increase in the demand for both lentiviral vectors, as well as expertise in their use and application,” said Gurutz Linazasoro, CEO of VIVEbiotech, in the press release. “This demand for lentivirals is increasing for therapies throughout the clinical stages and into commercialization. A higher number of early-stage cell and gene therapy developers now are requiring a longer-term partner in lentiviral supply that provides continuity throughout the clinical stages. VIVEbiotech has responded to this growth in requirement from the cell and gene therapy sector by constructing new facilities with increased cleanrooms to cater for the demand, and a renewed focus on innovation to continue leading the development of lentiviral vectors. This will enable us to utilize our sole lentiviral expertise and specialization to contribute towards moving gene therapies through the clinical process and to patients in a range of different conditions.”


The new facilities are set to be completed in April 2021, with the transition between the facilities completed by October 2021.

Source: VIVEbiotech